1. AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study. (15th June 2017) Authors: Takeuchi, T; Fleischmann, R; Schiff, M; Issa, M; Macias, W; Rooney, T; Zuckerman, S; Schlichting, D; McInnes, I Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis. (15th June 2017) Authors: Taylor, P; Zhu, B; Gaich, C; Zhang, X; DeLozier, AM; Schlichting, D; Patel, H; Durand, F; Fautrel, B Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 788 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0058 Effects of baricitinib on patients who stop methotrexate monotherapy and switch to baricitinib monotherapy. (15th June 2017) Authors: Fleischmann, R; Takeuchi, T; Schiff, M; Schlichting, D; Xie, L; Issa, M; Stoykov, I; Lisse, JR; Martinez-Osuna, P; Rooney, T; Zerbini, CA Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 789 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. (15th June 2017) Authors: Heijde, D van der; Durez, P; Schett, G; Naredo, E; Østergaard, M; Meszaros, G; Bello, N; Torre, I De la; Lopez-Romero, P; Schlichting, D; Nantz, E; Fleischmann, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗